Summary
KL PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €384,626 and a net result of €50,690. Equity is growing by about 9.5% per year across the filed financial years. Its solvency ranks better than 56% of 6,641 sector peers (NACE 64, financial year 2025). The company has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
29-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
31-12
Financial
Highest result from 2018 to 2025net €50,690 ▲3.4%
Operating result €83,834, net result €50,690, both a record.
30-06
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
25-06
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
28-06
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
29-06
NBB filing
Annual accounts filed
financial year 2021 · full format
2021
13-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
01-07
NBB filing
Annual accounts filed
financial year 2019 · micro format
2019
25-06
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
16-07
NBB filing
Annual accounts filed
financial year 2017 · full format
2017
29-06
NBB filing
Annual accounts filed
financial year 2016 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 16 annual accounts filed, the latest 10 are here; all are under Financials.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.